Evaxion A (EVAX) Receivables (2019 - 2025)
Evaxion A's (EVAX) quarterly Receivables came in at $424000.0 in Q2 2025, up 8.16% YoY from $392000.0 in Q2 2024, and up 552.31% on a QoQ basis from $65000.0 in Q4 2024.
Evaxion A (EVAX) Receivables (2019 - 2025) Analysis & Trends
Evaxion A (EVAX) has 7 years of Receivables data on file, last reported at $424000.0 in Q2 2025.
- Quarterly Receivables rose 8.16% year-over-year to $424000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $424000.0 (up 8.16% YoY) and the FY2024 annual result came in at $65000.0, down 96.84% from the prior year.
- Receivables climbed to $424000.0 in Q2 2025, from $65000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $2.8 million in Q4 2022 to a low of $65000.0 in Q4 2024.
- A 5-year average of $679111.1 and a median of $401000.0 in 2022 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables surged 123.9% — and 2023, when it slumped 96.14%.
- Tracing EVAX's Receivables over 5 years: stood at $1.3 million in 2021, then surged by 123.9% to $2.8 million in 2022, then tumbled by 96.14% to $108000.0 in 2023, then sank by 39.81% to $65000.0 in 2024, then soared by 552.31% to $424000.0 in 2025.
- The last three Receivables figures came in at $424000.0 (Q2 2025), $65000.0 (Q4 2024), and $392000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | - |
| 10 | Evaxion A | 27.94 Mn | 27.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 424,000.00 |
| Dec 31, 2024 | 65,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Dec 31, 2023 | 108,000.00 |
| Jun 30, 2023 | 425,000.00 |
| Dec 31, 2022 | 2.80 Mn |
| Jun 30, 2022 | 401,000.00 |
| Mar 31, 2022 | 245,000.00 |
| Dec 31, 2021 | 1.25 Mn |
| Dec 31, 2020 | 1.56 Mn |
| Dec 31, 2019 | 607,000.00 |